Knockout Mouse Catalog | Cyagen APAC
  1. Home
  2. Community
  3. Promotions
  4. BALB/c Strain TurboKnockout® ES Targeting
BALB/c Strain TurboKnockout® ES Cell Targeting Your New Drug Development Must-Have!

BALB/c is a laboratory-bred, albino strain of the house mouse, characterized by its immunodeficiency and extreme susceptibility to carcinogens. BALB/c mice are among the most widely used mouse strains across oncology, immunology, and nuclear medicine research, and are often the first option for animal experimentation models in new drug development projects. In addition, BALB/c mice are well-known for the production of plasmacytomas after injection with mineral oil, leading to their use in the preparation of monoclonal antibodies (mAbs).

Under normal circumstances, the BALB/c-derived embryonic stem (ES) cell proliferation is hard, and the corresponding ES Targeting model is even more difficult to construct. Cyagen has screened several batches of BALB/c-strain ES cells over two and a half years, testing several characteristics – including progenicity, karyotype stability, and totipotency - to finally provide screened BALB/c-derived ES cells suitable for generating targeted genetic models.

The TurboKnockout® service by Cyagen is based on traditional ES cell targeting techniques, which can be used for complex gene knockout projects to provide BALB/c mouse models with accurate genetic modification, 100% germline transmission (GLT), and no off-target effects. Compared with CRISPR/Cas9-based techniques, TurboKnockout® is free of patent disputes and is the technology of choice for drug development projects. For consultation and order, please call 86 20-31601779 or email service-apac@cyagen.com.

● Promotion Period: April 1st 2020 - May 31th 2020
● Eligibility: End clients in Asia Pacific region, excluded Japan
Service Deliverables Price
TurboKnockout® Knockout Mice 4 BALB/c TurboKnockout® Mice Inquire for price
TurboKnockout® Conditional Knockout/Knockin Mice 4 BALB/c TurboKnockout® Mice Inquire for price

How to Order

Request an online quote

We will respond to you in 1-2 business days

Your Name can not be empty

Please enter a valid email address.

Your Email can not be empty

Message can not be empty

TurboKnockout® BALB/c Service Advantages

Strict selection standard for BALB/c strain ES cells

Cyagen has successively selected several batches of BALB/c strain ES cells, among which each batch has been tested on several factors such as progenicity, karyotype stability, totipotency, reproductive chimerism, and final germline chimerism testing, to finally provide screened BALB/c-derived ES cells suitable for generating targeted genetic models.

Commonly-Used Mouse Strain for Oncology Research

BALB/c mice are extremely susceptible to carcinogens, leading to their wide use in oncology, immunology, nuclear medicine research, the preparation of monoclonal antibodies (mAbs), and are often the first option for animal experimentation models in new drug development projects.

No Off-Target Effects

TurboKnockout® is based on traditional ES cell targeting techniques, which can be used for complex genetic modification projects to provide BALB/c mouse models with accurate genetic modification, 100% germline transmission (GLT), and no off-target effects.

No Risk of Patent Infringements

Compared with CRISPR/Cas9 techniques, TurboKnockout® is free of patent disputes and is the technique of choice for new drug development projects.

Shorter Turnaround

Founders as fast as 6 months due to innovations that eliminate two generations of breeding: 1) super competent ES cell line generates 100% ESC-derived founders, avoiding the ‘chimera’ phase; and 2) a self-removing Neo selection cassette that circumvents the need to breed to Flp deleter mice.

客户引用文献3600篇,IF合计16463,被引用24757次

Reducing Hypothalamic Stem Cell Senescence Protects against Aging-Associated Physiological Decline.
Cell Metabolism PMID: 32004475 (2020) IF=22.415
Oxytocin-dependent reopening of a social reward learning critical period with MDMA.
Nature 569: 116-120 (2019) IF=41.577
Specific Decrease in B-Cell-Derived Extracellular Vesicles Enhances Post-Chemotherapeutic CD8+ T Cell Responses.
Immunity PMID: 30770248 (2019) IF=19.734
VSIG4 mediates transcriptional inhibition of Nlrp3 and Il-1β in macrophages.
Gut 68: 301-312 (2019) IF=17.016